Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RIVAL 01

Next Previous
Drug Profile

RIVAL 01

Alternative Names: RIVAL-01; TAK-605; TBio-6517

Latest Information Update: 04 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Turnstone Biologics
  • Developer Takeda; Turnstone Biologics
  • Class Antibodies; Antineoplastics; Cancer vaccines; Cytokines; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fms-like tyrosine kinase 3 expression stimulants; Immunologic cytotoxicity; Interleukin-12 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 23 Jan 2023 Turnstone Biologics terminates Phase-I/II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Canada, South Korea and USA due to Sponsor decision (Intratumoural) (NCT04301011)
  • 13 Apr 2021 Takeda anticipates the approval of RIVAL 01 for Multiple cancers in 2025/2026 (Takeda pipeline, April 2021)
  • 02 Jun 2020 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in South Korea, Canada (Intratumoural) (NCT04301011)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top